Name | Number of supported studies | Average coverage | |
---|---|---|---|
classical monocyte | 10 studies | 31% ± 11% | |
monocyte | 8 studies | 21% ± 3% | |
plasmacytoid dendritic cell | 7 studies | 26% ± 5% | |
macrophage | 7 studies | 22% ± 4% | |
non-classical monocyte | 6 studies | 33% ± 9% | |
myeloid cell | 5 studies | 22% ± 4% | |
microglial cell | 5 studies | 26% ± 7% | |
conventional dendritic cell | 4 studies | 30% ± 13% | |
epithelial cell | 4 studies | 32% ± 6% | |
dendritic cell | 4 studies | 36% ± 14% | |
neutrophil | 3 studies | 20% ± 5% | |
adipocyte | 3 studies | 21% ± 2% | |
ciliated cell | 3 studies | 21% ± 1% | |
type I pneumocyte | 3 studies | 18% ± 3% |
Insufficient scRNA-seq data for expression of PRKCD at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
prostate | 100% | 4539.03 | 245 / 245 | 100% | 123.51 | 501 / 502 |
skin | 100% | 3576.39 | 1807 / 1809 | 100% | 105.31 | 470 / 472 |
bladder | 100% | 3981.95 | 21 / 21 | 99% | 80.93 | 501 / 504 |
thymus | 100% | 6191.33 | 653 / 653 | 99% | 129.08 | 601 / 605 |
breast | 100% | 3960.36 | 459 / 459 | 99% | 101.74 | 1108 / 1118 |
lung | 100% | 5639.77 | 577 / 578 | 99% | 64.25 | 1146 / 1155 |
esophagus | 99% | 2526.39 | 1431 / 1445 | 100% | 62.62 | 183 / 183 |
stomach | 98% | 3824.78 | 353 / 359 | 100% | 67.95 | 285 / 286 |
ovary | 97% | 1473.13 | 174 / 180 | 99% | 80.72 | 427 / 430 |
pancreas | 97% | 1669.87 | 318 / 328 | 99% | 82.15 | 176 / 178 |
intestine | 96% | 3267.34 | 925 / 966 | 100% | 66.42 | 525 / 527 |
kidney | 100% | 2477.03 | 89 / 89 | 94% | 42.51 | 845 / 901 |
uterus | 94% | 1362.15 | 160 / 170 | 98% | 57.66 | 450 / 459 |
adrenal gland | 100% | 7423.83 | 258 / 258 | 58% | 35.26 | 133 / 230 |
brain | 67% | 1099.15 | 1782 / 2642 | 62% | 17.41 | 437 / 705 |
adipose | 100% | 4489.26 | 1204 / 1204 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 166.07 | 29 / 29 |
peripheral blood | 100% | 14512.35 | 929 / 929 | 0% | 0 | 0 / 0 |
spleen | 100% | 7298.44 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 47.29 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 72.75 | 1 / 1 |
blood vessel | 100% | 2595.32 | 1330 / 1335 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 96% | 47.61 | 77 / 80 |
heart | 79% | 1357.32 | 678 / 861 | 0% | 0 | 0 / 0 |
liver | 23% | 230.57 | 52 / 226 | 46% | 13.62 | 185 / 406 |
muscle | 24% | 257.80 | 196 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_2000753 | Biological process | positive regulation of glucosylceramide catabolic process |
GO_0032956 | Biological process | regulation of actin cytoskeleton organization |
GO_0018105 | Biological process | peptidyl-serine phosphorylation |
GO_0030837 | Biological process | negative regulation of actin filament polymerization |
GO_2000755 | Biological process | positive regulation of sphingomyelin catabolic process |
GO_0010469 | Biological process | regulation of signaling receptor activity |
GO_0043488 | Biological process | regulation of mRNA stability |
GO_0071447 | Biological process | cellular response to hydroperoxide |
GO_0034644 | Biological process | cellular response to UV |
GO_0007165 | Biological process | signal transduction |
GO_0006974 | Biological process | DNA damage response |
GO_0018107 | Biological process | peptidyl-threonine phosphorylation |
GO_0042307 | Biological process | positive regulation of protein import into nucleus |
GO_0023021 | Biological process | termination of signal transduction |
GO_0046627 | Biological process | negative regulation of insulin receptor signaling pathway |
GO_0043687 | Biological process | post-translational protein modification |
GO_0090331 | Biological process | negative regulation of platelet aggregation |
GO_0032147 | Biological process | activation of protein kinase activity |
GO_0050732 | Biological process | negative regulation of peptidyl-tyrosine phosphorylation |
GO_2000304 | Biological process | positive regulation of ceramide biosynthetic process |
GO_2000303 | Biological process | regulation of ceramide biosynthetic process |
GO_0035556 | Biological process | intracellular signal transduction |
GO_0050728 | Biological process | negative regulation of inflammatory response |
GO_0050821 | Biological process | protein stabilization |
GO_0051490 | Biological process | negative regulation of filopodium assembly |
GO_0016064 | Biological process | immunoglobulin mediated immune response |
GO_0042742 | Biological process | defense response to bacterium |
GO_0006915 | Biological process | apoptotic process |
GO_0043407 | Biological process | negative regulation of MAP kinase activity |
GO_0032930 | Biological process | positive regulation of superoxide anion generation |
GO_0090398 | Biological process | cellular senescence |
GO_0042100 | Biological process | B cell proliferation |
GO_0032079 | Biological process | positive regulation of endodeoxyribonuclease activity |
GO_0038096 | Biological process | Fc-gamma receptor signaling pathway involved in phagocytosis |
GO_0034351 | Biological process | negative regulation of glial cell apoptotic process |
GO_2001235 | Biological process | positive regulation of apoptotic signaling pathway |
GO_0006468 | Biological process | protein phosphorylation |
GO_0008631 | Biological process | intrinsic apoptotic signaling pathway in response to oxidative stress |
GO_0032091 | Biological process | negative regulation of protein binding |
GO_1900163 | Biological process | positive regulation of phospholipid scramblase activity |
GO_0060326 | Biological process | cell chemotaxis |
GO_0070301 | Biological process | cellular response to hydrogen peroxide |
GO_0042119 | Biological process | neutrophil activation |
GO_0035307 | Biological process | positive regulation of protein dephosphorylation |
GO_1904385 | Biological process | cellular response to angiotensin |
GO_0035578 | Cellular component | azurophil granule lumen |
GO_0005576 | Cellular component | extracellular region |
GO_0005886 | Cellular component | plasma membrane |
GO_0048471 | Cellular component | perinuclear region of cytoplasm |
GO_0005739 | Cellular component | mitochondrion |
GO_0070062 | Cellular component | extracellular exosome |
GO_0005654 | Cellular component | nucleoplasm |
GO_0036019 | Cellular component | endolysosome |
GO_0005911 | Cellular component | cell-cell junction |
GO_0016363 | Cellular component | nuclear matrix |
GO_0005783 | Cellular component | endoplasmic reticulum |
GO_0005829 | Cellular component | cytosol |
GO_0005737 | Cellular component | cytoplasm |
GO_0005634 | Cellular component | nucleus |
GO_0019899 | Molecular function | enzyme binding |
GO_0008047 | Molecular function | enzyme activator activity |
GO_0004715 | Molecular function | non-membrane spanning protein tyrosine kinase activity |
GO_0106310 | Molecular function | protein serine kinase activity |
GO_0004699 | Molecular function | diacylglycerol-dependent, calcium-independent serine/threonine kinase activity |
GO_0019901 | Molecular function | protein kinase binding |
GO_0004674 | Molecular function | protein serine/threonine kinase activity |
GO_0043560 | Molecular function | insulin receptor substrate binding |
GO_0004672 | Molecular function | protein kinase activity |
GO_0046872 | Molecular function | metal ion binding |
GO_0005524 | Molecular function | ATP binding |
GO_0004697 | Molecular function | diacylglycerol-dependent serine/threonine kinase activity |
GO_0005515 | Molecular function | protein binding |
Gene name | PRKCD |
Protein name | Protein kinase C delta type (EC 2.7.11.13) (Tyrosine-protein kinase PRKCD) (EC 2.7.10.2) (nPKC-delta) [Cleaved into: Protein kinase C delta type regulatory subunit; Protein kinase C delta type catalytic subunit (Sphingosine-dependent protein kinase-1) (SDK1)] Protein kinase C delta Protein kinase C gamma type |
Synonyms | PKCD |
Description | FUNCTION: Calcium-independent, phospholipid- and diacylglycerol (DAG)-dependent serine/threonine-protein kinase that plays contrasting roles in cell death and cell survival by functioning as a pro-apoptotic protein during DNA damage-induced apoptosis, but acting as an anti-apoptotic protein during cytokine receptor-initiated cell death, is involved in tumor suppression as well as survival of several cancers, is required for oxygen radical production by NADPH oxidase and acts as positive or negative regulator in platelet functional responses . Negatively regulates B cell proliferation and also has an important function in self-antigen induced B cell tolerance induction (By similarity). Upon DNA damage, activates the promoter of the death-promoting transcription factor BCLAF1/Btf to trigger BCLAF1-mediated p53/TP53 gene transcription and apoptosis . In response to oxidative stress, interact with and activate CHUK/IKKA in the nucleus, causing the phosphorylation of p53/TP53 . In the case of ER stress or DNA damage-induced apoptosis, can form a complex with the tyrosine-protein kinase ABL1 which trigger apoptosis independently of p53/TP53 . In cytosol can trigger apoptosis by activating MAPK11 or MAPK14, inhibiting AKT1 and decreasing the level of X-linked inhibitor of apoptosis protein (XIAP), whereas in nucleus induces apoptosis via the activation of MAPK8 or MAPK9. Upon ionizing radiation treatment, is required for the activation of the apoptosis regulators BAX and BAK, which trigger the mitochondrial cell death pathway. Can phosphorylate MCL1 and target it for degradation which is sufficient to trigger for BAX activation and apoptosis. Is required for the control of cell cycle progression both at G1/S and G2/M phases. Mediates phorbol 12-myristate 13-acetate (PMA)-induced inhibition of cell cycle progression at G1/S phase by up-regulating the CDK inhibitor CDKN1A/p21 and inhibiting the cyclin CCNA2 promoter activity. In response to UV irradiation can phosphorylate CDK1, which is important for the G2/M DNA damage checkpoint activation (By similarity). Can protect glioma cells from the apoptosis induced by TNFSF10/TRAIL, probably by inducing increased phosphorylation and subsequent activation of AKT1 . Is highly expressed in a number of cancer cells and promotes cell survival and resistance against chemotherapeutic drugs by inducing cyclin D1 (CCND1) and hyperphosphorylation of RB1, and via several pro-survival pathways, including NF-kappa-B, AKT1 and MAPK1/3 (ERK1/2). Involved in antifungal immunity by mediating phosphorylation and activation of CARD9 downstream of C-type lectin receptors activation, promoting interaction between CARD9 and BCL10, followed by activation of NF-kappa-B and MAP kinase p38 pathways (By similarity). Can also act as tumor suppressor upon mitogenic stimulation with PMA or TPA. In N-formyl-methionyl-leucyl-phenylalanine (fMLP)-treated cells, is required for NCF1 (p47-phox) phosphorylation and activation of NADPH oxidase activity, and regulates TNF-elicited superoxide anion production in neutrophils, by direct phosphorylation and activation of NCF1 or indirectly through MAPK1/3 (ERK1/2) signaling pathways . May also play a role in the regulation of NADPH oxidase activity in eosinophil after stimulation with IL5, leukotriene B4 or PMA . In collagen-induced platelet aggregation, acts a negative regulator of filopodia formation and actin polymerization by interacting with and negatively regulating VASP phosphorylation . Downstream of PAR1, PAR4 and CD36/GP4 receptors, regulates differentially platelet dense granule secretion; acts as a positive regulator in PAR-mediated granule secretion, whereas it negatively regulates CD36/GP4-mediated granule release . Phosphorylates MUC1 in the C-terminal and regulates the interaction between MUC1 and beta-catenin . The catalytic subunit phosphorylates 14-3-3 proteins (YWHAB, YWHAZ and YWHAH) in a sphingosine-dependent fashion (By similarity). Phosphorylates ELAVL1 in response to angiotensin-2 treatment . Phosphorylates mitochondrial phospholipid scramblase 3 (PLSCR3), resulting in increased cardiolipin expression on the mitochondrial outer membrane which facilitates apoptosis . Phosphorylates SMPD1 which induces SMPD1 secretion . . |
Accessions | C9K0E3 ENST00000650940.1 ENST00000697588.1 ENST00000651505.1 ENST00000654719.1 [Q05655-1] Q05655 ENST00000464818.1 A0A8V8TMH8 C9JZU8 ENST00000478843.5 A0A494C1T7 ENST00000487897.5 ENST00000477794.2 ENST00000330452.8 [Q05655-1] ENST00000650739.1 [Q05655-1] C9J9P1 ENST00000394729.6 [Q05655-1] A0A494C125 A0A494BZX2 ENST00000652449.1 [Q05655-1] |